VolitionRx shares surged over 70% pre-market after unveiling a potential breakthrough in cancer detection. The company announced it successfully isolated over 99% pure circulating tumor-derived DNA from blood samples. This innovation solves a key liquid biopsy bottleneck by removing background healthy cell DNA, which the Chief Scientific Officer hailed as a potential "world-first."